Suggested remit: To appraise the clinical and cost effectiveness of futibatinib within its marketing authorisation for treating cholangiocarcinoma.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
Process |
STA Standard
|
ID number |
6302
|
Provisional Schedule
Committee meeting |
02 July 2024 |
Expected publication |
11 September 2024 |
Project Team
Email enquiries
External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
Companies sponsors |
Taiho Pharma Europe (futibatinib) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
AMMF – The Cholangiocarcinoma Charity |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Associated public health groups |
None |
Comparator companies |
Incyte Biosciences (pemigatinib) (confidentiality agreement returned, participating) |
|
Hospira UK (fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Medac (folinic acid, fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Ranbaxy, a Sun Pharmaceutical company (oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Seacross Pharmaceuticals (oxaliplatin) (confidentiality agreement not returned, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
Date
|
Update
|
20 November 2023
|
Invitation to participate |
04 October 2023 - 01 November 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6302 |
03 August 2023
|
In progress. DHSC referral received |
06 July 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual